ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, BCR/ABL1 fusion protein enhances survival of hematopoietic stem cells and exert antiapoptotic activity in CML cell progenitors and mediating many of the processes like imatinib resistance, disease progression and response [9].